The material was released this Wednesday, 30, by the New England Journal Of Medicine; results also showed important and negative side effects in patients
In all, 1,800 people participated in the test, which lasted 18 months and whose results were released this Wednesday.
Scientists celebrated the results of a clinical trial which proved that a damn it delays cognitive decline in patients with Alzheimer’s, in addition to pointing out important side effects. The material was released on Wednesday, 30, by the New England Journal Of Medicine. The results of the advanced clinical trial carried out with 1,800 people for a year and a half showed a 27% reduction in cognitive impairment in patients who received lecanemab, a drug developed by the Japanese group Eisai and the American company Biogen. However, the results also point to side effects, sometimes serious.
In total, 17.3% of patients who received the drug experienced brain hemorrhages, compared with 9% of the placebo group. Furthermore, 12.6% of the patients had cerebral edema, against only 1.7% of the placebo group. The mortality rate was almost the same in both groups: 0.7% in those who received the drug and 0.8% in those who received a placebo. “It’s the first medicine that offers a real treatment option for people with Alzheimer’s,” said Bart De Strooper, director of the British Institute for Dementia Research. “While the clinical benefits seem somewhat limited, it is expected that they will become more evident if the drug is given over a longer period of time,” he said.
🇧🇷With information from AFP
Source: Jovempan
I have been working as a journalist for over 10 years. In that time, I have covered the news from all corners of the world, and written about everything from politics to business.I’m now a full-time author, and my work can be found at Global happenings. My aim is to bring you up-to-date news and views on global affairs, in a format that is easy to read and understand.
